SpaceX and psychedelic biotech sectors see significant investment interest

SpaceX is receiving a buy rating from Pivotal Research, which suggests the company could reach a $2 trillion valuation if it successfully achieves rapid reusability for its Starship launch system. Analyst Jeffrey Wlodarczak noted that the investment thesis hinges on overcoming the engineering bottleneck of making Starship function like a commercial aircraft, capable of 20 to 50 flights with inexpensive refurbishment.

In the biotechnology sector, significant capital is flowing into psychedelic research and therapies. Following an executive order supporting such research, the sector has seen strong market performance. A major milestone in this space occurred in July when Eli Lilly agreed to acquire Atai Beckley for approximately $2.8 billion upfront, with an additional $1 billion contingent on regulatory and development milestones.